GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Net Income From Continuing Operations

Haleon (XTER:H6D0) Net Income From Continuing Operations : €1,324 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Haleon's net income from continuing operations for the three months ended in Mar. 2024 was €516 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €1,324 Mil.

Haleon Net Income From Continuing Operations Historical Data

The historical data trend for Haleon's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Net Income From Continuing Operations Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
810.35 1,304.82 1,693.50 1,286.65 1,289.60

Haleon Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 470.40 367.10 433.71 8.13 515.53

Haleon Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,324 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleon (XTER:H6D0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Net Income From Continuing Operations
Comparable Companies
LSE:HIK LSE:HCM LSE:INDV LSE:BMK LSE:APH LSE:ANCR LSE:EAH LSE:AGY LSE:CEL LSE:STX ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NBIX
Traded in Other Exchanges
HLNCF:USA HLN:USA HLN1:Mexico HLNl:UK HLN:UK
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Website
https://www.haleon.com
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Haleon (XTER:H6D0) Headlines

No Headlines